Rational application of drug promiscuity in medicinal chemistry

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Frank SD. Target-based drug discovery: is something wrong? Drug Discov. Today 10(2), 139–147 (2005).
  MedlineGoogle Scholar
• 2 Chartier M, Morency LP, Zylber MI, Najmanovich RJ. Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects. BMC Pharmacol. Toxicol. 18, 18 (2017).
  MedlineGoogle Scholar
• 3 Guo ZR. Drug promiscuity. Acta Pharm. Sin. 46(4), 361–369 (2011).
  CASGoogle Scholar
• 4 Howard HR, Lowe JA, Seeger TF et al. 3-benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 39(1), 143–148 (1996).
  Medline CASGoogle Scholar
• 5 Hu Y, Bajorath J. High-resolution view of compound promiscuity [version 2; referees: 3 approved]. F1000Res. 2, 144 (2013).
  MedlineGoogle Scholar
• 6 Jasial S, Hu Y, Bajorath J. Determing the degree of promiscuity of extensively assayed compounds. PLoS ONE 11(4), e0153873 (2016).
  MedlineGoogle Scholar
• 7 Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electr. 10(6), 836–843 (1999).
  Medline CASGoogle Scholar
• 8 Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2(9), 695–702 (2003).
  Medline CASGoogle Scholar
• 9 Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673–683 (2004).
  Medline CASGoogle Scholar
• 10 Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5(8), 689–702 (2006).
  Medline CASGoogle Scholar
• 11 Fernandez A. Is there a case for selectively promiscuous anticancer drugs? Drug Discov. Today 14(1), 1–5 (2009).
  Medline CASGoogle Scholar
• 12 Cumming JG, Raymond V, Finlay M, Giordanetto F et al. Potential strategies for increasing drug-discovery productivity. Future Med. Chem. 6(5), 515–527 (2014).
  CASGoogle Scholar
• 13 Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr. Opin. Struc. Biol. 16(1), 127–136 (2006).
  Medline CASGoogle Scholar
• 14 Tarcasy Á, Keserű GM. Contributions of molecular properties to drug promiscuity. J. Med. Chem. 56(5), 1789–1795 (2013). •• An excellent review mainly focused on the contribution of molecular properties to drug promiscuity.
  MedlineGoogle Scholar
• 15 Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J. Med. Chem. 57(19), 7874–7887 (2014). • This perspective mainly introduces advantages and disadvantages of multi-target versus combination therapies, discussion of potential drug promiscuity arising from off-target effects, comment on drug repurposing.
  Medline CASGoogle Scholar
• 16 Morphy R, Rankovic Z. Designed mutiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21), 6523–6543(2005).
  Medline CASGoogle Scholar
• 17 Korcsmáros T, Szalay MS, Böde C, Kovács IA, Csermely P. How to design muti-target drugs: target search options in cellular networks. Expert Opin. Drug Discov. 2(6), 799–808 (2007).
  Medline CASGoogle Scholar
• 18 Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 7, 3 (2018). •• Review of recent advance in the multi-target drug discovery for the treatment of the complex disease.
  MedlineGoogle Scholar
• 19 Tan Z, Chaudhai R, Zhang SX. Polypharmacology in drug development: a minireview of current technologies. ChemMedChem 11(12), 1211–1218 (2016).
  Medline CASGoogle Scholar
• 20 Handler N, Buschmann H. Drug Selectivity An Evolving Concept In Medicinal Chemistry. Wiley VCH Verlag GmbH & Co KGaA, Weinheim, Germany, 161–206 (2018).
  Google Scholar
• 21 Priest BT, Erdemli G. Phenotypic screening in the 21st century. Front. Pharmacol. 5, 264 (2014).
  MedlineGoogle Scholar
• 22 Warchal SJ, Unciti-Broceta A, Carragher NO. Next generation phenotypic screening. Future Med. Chem. 8(11), 1331–1347 (2016).
  CASGoogle Scholar
• 23 Escobar-Chavez JJ, Dominguez-Delgado CL, Rodriguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des. Dev. Ther. 5, 211–224 (2011).
  Medline CASGoogle Scholar
• 24 Hackling A, Ghosh R, Perachon S et al. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J. Med. Chem. 46(18), 3883–3899 (2003).
  Medline CASGoogle Scholar
• 25 Mor M, Rivara S, Lodola A et al. Cyclohexylcarbamic acid 3’- or 4’-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 47(21), 4998–5008 (2004).
  Medline CASGoogle Scholar
• 26 De Simone A, Ruda GF, Albani C et al. Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase. Chem. Commun. 50(38), 4904–4907 (2014).
  Medline CASGoogle Scholar
• 27 Joyce JN, Millan MJ. Dopamine D₃ receptor antagonists as therapeutic agents. Drug Discov. Today 10(13), 917–925 (2005).
  Medline CASGoogle Scholar
• 28 Peters JU, Hert J, Bissantz C et al. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discov. Today 17(7–8), 325–335 (2012). • This review mainly discusses the trends in the assessment of pharmacological promiscuity and proposes some strategies to enable early detection and mitigation.
  MedlineGoogle Scholar
• 29 Elias O, Kovacs Z, Wagner G, Nemethy Z, Tarcsay A, Greiner I. Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. Bioorg. Med. Chem. Lett. 26(17), 4211–4215 (2016).
  Medline CASGoogle Scholar
• 30 Yang EG, Mustafa N, Tan EC et al. Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines. J. Med. Chem. 59(18), 8233–8262 (2016).
  Medline CASGoogle Scholar
• 31 Albrecht W, Unger A, Bauer SM, Laufer SA. Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a dual p38α MAPK/PDE-4 inhibitor with activity against TNFα-related diseases. J. Med. Chem. 60(13), 5290–5305 (2017).
  Medline CASGoogle Scholar
• 32 Morphy R, Rankovic Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Design 15(6), 587–600 (2009).
  Medline CASGoogle Scholar
• 33 Lairmore TC, Dou S, Howe JR et al. A 1.5-megabase yeast artificial chromosome contig from human chromosome 10q11.2 connecting three genetic loi (Ret, D10S94, and D10S102) closely linked to MEN2A locus. Proc. Natl Acad. Sci. USA 90(2), 492–496 (1993).
  Medline CASGoogle Scholar
• 34 Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486(7401), 80–84 (2012).
  Medline CASGoogle Scholar
• 35 Yu JH, Ahn S, Kim HJ et al. Polypharmacology of N6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) and related A3 Adenosine receptor ligands: peroxisome proliferator activated receptor (PPAR) γ partial agonist and PPARδ antagonist activity suggests their antidiabetic potential. J. Med. Chem. 60(17), 7459–7475 (2017).
  Medline CASGoogle Scholar
• 36 Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53(7), 2719–2740 (2010).
  Medline CASGoogle Scholar
• 37 Gilberg E, Jasial S, Stumpfe D, Dimova D, Bajorath J. Highly promiscuous small molecules from biological screening assays include many pan-assay interference compounds but also candidates for polypharmacology. J. Med. Chem. 59(22), 10285–10290 (2016). •• Provides a way to obtain the leads for further exploring multi-target activities and the molecular basis of polypharmacology.
  Medline CASGoogle Scholar
• 38 Klug DM, Gelb MH, Pollastri MP. Repurposing strategies for tropical disease drug discovery. Bioorg. Med. Chem. Lett. 26(11), 2569–2576 (2016). •• This digest describes applications of different repurposing approaches for neglected tropical diseases.
  Medline CASGoogle Scholar
• 39 Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 321(5886), 263–266 (2008).
  Medline CASGoogle Scholar
• 40 Zhao Z, Martin C, Fan R, Bourne PE, Xie L. Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology. BMC Bioinformatics 17, 90 (2016).
  MedlineGoogle Scholar
• 41 Ma DL, Chan DS, Leung CH. Drug repositioning by structure-based virtual screening. Chem. Soc. Rev. 42(5), 2130–2141 (2013).
  Medline CASGoogle Scholar
• 42 Singh N, Halliday AC, Thomas JM et al. A safe lithium mimetic for bipolar disorder. Nat. Commun. 4, 1332–1338 (2013).
  MedlineGoogle Scholar
• 43 Austin CP, Brady LS, Insel TR, Collins FS. NIH Molecular Libraries Initiative. Science 306(5699), 1138–1139 (2004).
  Medline CASGoogle Scholar
• 44 Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. Oral. Oncol. 48(10), 997–1006 (2012).
  Medline CASGoogle Scholar
• 45 Qu Y, Gharbi N, Yuan X et al. Axitinib blocks Wnt/beta-catenin signaling and directs asymmetric cell division in cancer. Proc. Natl Acad. Sci. USA 113(33), 9339–9344 (2016).
  Medline CASGoogle Scholar
• 46 Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 258(5082), 593–597 (1992).
  Medline CASGoogle Scholar
• 47 Li H, Liu A, Zhao Z et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD), identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J. Med. Chem. 54(15), 5592–5596 (2011).
  Medline CASGoogle Scholar
• 48 Li H, Xiao H, Lin L et al. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J. Med. Chem. 57(3), 632–641 (2014).
  Medline CASGoogle Scholar
• 49 Pollastri MP, Campbell RK. Target repurposing for neglected disease. Future Med. Chem. 3(10), 1307–1315 (2011). • Describes the overarching strategy of target repurposing as a tool for initiating and prosecuting neglected disease drug discovery programs.
  CASGoogle Scholar
• 50 Parsons M, Worthey EA, Ward PA, Mottram JC. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 6, 127 (2005).
  MedlineGoogle Scholar
• 51 Tu XM, Kumar P, Li ZY, Wang CC. Aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei. J. Biol. Chem. 281(14), 9677–9687 (2006).
  Medline CASGoogle Scholar
• 52 Ochiana SO, Pandarinath V, Wang ZX et al. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. Eur. J. Med. Chem. 62, 777–784 (2013).
  Medline CASGoogle Scholar
• 53 Patel G, Karver CE, Behera R et al. Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. J. Med. Chem. 56(10), 3820–3832 (2013).
  Medline CASGoogle Scholar
• 54 Guo ZR. Strategy of molecular drug design: activity and druggability. Acta Pharm. Sin. 45(5), 539–547 (2010).
  CASGoogle Scholar
• 55 Bowes J, Brown AJ, Hamon J et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11(12), 909–922 (2012).
  Medline CASGoogle Scholar
• 56 Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102(23), 2836–2841 (2000).
  Medline CASGoogle Scholar
• 57 Dosa PI, Ward T, Walters MA, Kim SW. Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism. ACS Med. Chem. Lett. 4(2), 254–258 (2013).
  Medline CASGoogle Scholar
• 58 Louvel J, Carvalho JF, Yu Z et al. Removal of human ether-a-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues. J. Med. Chem. 56(23), 9427–9440 (2013).
  Medline CASGoogle Scholar
• 59 Mei YC, Yang BW. Application of amide bioisosteres in the optimization of lead compounds. Prog. Chem. 28(9), 1406–1416 (2016).
  CASGoogle Scholar
• 60 Nair AG, Wong MK, Shu Y et al. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles. Bioorg. Med. Chem. Lett. 24(4), 1085–1088 (2014).
  Medline CASGoogle Scholar
• 61 von Kleist L, Michaelis S, Bartho K et al. Identification of potential off-target toxicity liabilities of catechol-o-methyltransferase inhibitors by differential competition capture compound mass spectrometry. J. Med. Chem. 59(10), 4664–4675 (2016).
  Medline CASGoogle Scholar
• 62 Koster H, Little DP, Luan P et al. Capture compound mass spectrometry: a technology for the investigation of small molecule protein interactions. Assay Drug Dev. Technol. 5(3), 381–390 (2007).
  MedlineGoogle Scholar
• 63 Prati F, Cavalli A, Bolognesi ML. Navigating the chemical space of multi-target directed ligands: from hybrids to fragments in Alzheimer's disease. Molecules 21(4), 466–477 (2016).
  MedlineGoogle Scholar